Regulated necrosis role in inflammation and repair in acute kidney injury

Front Immunol. 2023 Nov 24:14:1324996. doi: 10.3389/fimmu.2023.1324996. eCollection 2023.

Abstract

Acute kidney injury (AKI) frequently occurs in patients with chronic kidney disease (CKD) and in turn, may cause or accelerate CKD. Therapeutic options in AKI are limited and mostly relate to replacement of kidney function until the kidneys recover spontaneously. Furthermore, there is no treatment that prevents the AKI-to-CKD transition. Regulated necrosis has recently emerged as key player in kidney injury. Specifically, there is functional evidence for a role of necroptosis, ferroptosis or pyroptosis in AKI and the AKI-to-CKD progression. Regulated necrosis may be proinflammatory and immunogenic, triggering subsequent waves of regulated necrosis. In a paradigmatic murine nephrotoxic AKI model, a first wave of ferroptosis was followed by recruitment of inflammatory cytokines such as TWEAK that, in turn, triggered a secondary wave of necroptosis which led to persistent kidney injury and decreased kidney function. A correct understanding of the specific forms of regulated necrosis, their timing and intracellular molecular pathways may help design novel therapeutic strategies to prevent or treat AKI at different stages of the condition, thus improving patient survival and the AKI-to-CKD transition. We now review key regulated necrosis pathways and their role in AKI and the AKI-to-CKD transition both at the time of the initial insult and during the repair phase following AKI.

Keywords: acute kidney injury; cell death; chronic kidney disease; fibrosis; inflammation; tissue repair.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury* / metabolism
  • Animals
  • Apoptosis
  • Humans
  • Inflammation / complications
  • Mice
  • Necrosis
  • Renal Insufficiency, Chronic* / metabolism

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. ISCIII/Fondos FEDER (PI22/00469, PI22/00050, PI21/1453, PI19/00588, ERA-PerMed-JTC2022 (SPAREKID AC22/00027), RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union – NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR) and SPACKDc PMP21/00109. Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA_COR-CM. COST Action PERMEDIK CA21165, supported by COST (European Cooperation in Science and Technology) 2023-2027. PREVENTCKD Consortium Project ID: 101101220 Program: EU4H DG/Agency: HADEA. Salary support: RICORS2040 to NV-G, Ramon y Cajal program to ABS, MICIU to JG-M, Juan de la Cierva incorporación program (IJC2018-035187-I) to SR-M.